Drug Patent Expirations in December 2006

Dec. 6, 2006 – Applicant :: TRADENAME :: generic name

Watson Labs :: DILACOR XR :: diltiazem hydrochloride
Bracco :: PROHANCE :: gadoteridol
Bracco :: PROHANCE MULTIPACK :: gadoteridol
Baxter Hlthcare :: EXTRANEAL :: icodextrin
Glaxosmithkline :: ZOFRAN ODT :: ondansetron
Glaxosmithkline :: ZOFRAN :: ondansetron hydrochloride
Glaxosmithkline :: ZOFRAN IN PLASTIC CONTAINER :: ondansetron hydrochloride
Glaxosmithkline :: ZOFRAN PRESERVATIVE FREE :: ondansetron hydrochloride
Glaxosmithkline :: PAXIL CR :: paroxetine hydrochloride
Novartis :: LAMISIL :: terbinafine
Novartis :: LAMISIL :: terbinafine hydrochloride
Novartis :: LAMISIL AT :: terbinafine hydrochloride

This list does not discriminate between dominant and non-dominant patents. Listed drugs above may be protected by additional patents and other regulatory protections.

For more details, visit DrugPatentWatch at http://www.DrugPatentWatch.com

To subscribe to the free Patent Expiration Bulletin, visit http://www.DrugPatentWatch.com/newsletter

All trademarks and applicant names are the property of their respective owners or licensors. Drug patent expiration data is presented “as is.” Use of this information is at your own risk. No warranty is expressed or implied. There is no warranty that the drug patent expriation information is error free.

ABOUT DrugPatentWatch ( http://www.DrugPatentWatch.com )

DrugPatentWatch provides information on drug patent expirations. Complete details are provided for all FDA-approved small molecule drugs. Sales information is available for top-selling drugs. This value-added information supports the critical business functions of patent agents and attorneys, pharmaceutical companies, wholesalers, healthcare payers, and investors.

— End —